# Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial

> **NCT07481955** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Freya Biosciences ApS** · enrollment: 120 (estimated)

## Conditions studied

- Bacterial Vaginosis (BV)

## Interventions

- **DRUG:** FB 301
- **DRUG:** Chlorhexidine 0.5%
- **DRUG:** metronidazole 500 mg

## Key facts

- **NCT ID:** NCT07481955
- **Lead sponsor:** Freya Biosciences ApS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-16
- **Primary completion:** 2027-03-03
- **Final completion:** 2027-04-21
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-20

## Collaborators

- CRS Clinical Research Services Berlin GmbH

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07481955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07481955, "Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial". Retrieved via AI Analytics 2026-07-23 from https://api.ai-analytics.org/clinical/NCT07481955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*